Tepha in $10.7m financing:
This article was originally published in Clinica
Tepha, a developer of absorbable devices for therapeutic applications, has closed a $10.7m venture capital financing in a bid to support the development of its TephaFLEX biopolymer technology platform, which it licensed from Metabolix. The funding was led by the Vertical Group, and backed by Integra Ventures, Novartis Venture Fund and Westfield Life Sciences Fund. Cambridge, Massachusetts-based Tepha is currently working with several companies to incorporate the TephaFLEX into the development of other devices, such as surgical meshes, haemostats, intra-cardiac devices, absorbable stents, ligament and tendon repair devices and drug delivery systems. The firm has received US marketing clearances for its TephaFLEX absorbable and surgical mesh.